| A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis. | |
| | |
MedLine Citation:
|
PMID: 23292116 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
PURPOSE: Methotrexate (MTX) is one of the most widely studied and effective therapeutics agents available to treat many solid tumors, hematologic malignancies, and autoimmune diseases such as rheumatoid arthritis; however, the poor pharmacokinetic and narrow safety margin of the drug limits the therapeutic outcomes of conventional drug delivery systems. For an improved delivery of MTX, several pathophysiological features such as angiogenesis, enhanced permeability and retention effects, acidosis, and expression of specific antigens and receptors can be used either as targets or as tools for drug delivery. METHODS: There are many novel delivery systems developed to improve the pitfalls of MTX therapy ranged from polymeric conjugates such as human serum albumin, liposomes, microspheres, solid lipid nanoparticles, polymeric nanoparticles, dendrimers, polymeric micelles, in situ forming hydrogels, carrier erythrocyte, and nanotechnology-based vehicles such as carbon nanotubes, magnetic nanoparticles, and gold nanoparticles. Some are further modified with targeting ligands for active targeting purposes. RESULTS: Such delivery systems provide prolonged plasma profile, enhanced and specific activity in vitro and in vivo in animal models. Nevertheless, more complementary studies are needed before they can be applied in human. CONCLUSION: This review deals with the challenges of conventional systems and achievements of each pharmaceutical class of novel drug delivery vehicle. |
| | |
Authors:
|
Samira Sadat Abolmaali; Ali Mohammad Tamaddon; Rassoul Dinarvand |
Related Documents
:
|
23738076 - Mri-guided focused ultrasound as a new method of drug delivery. 23416056 - A functional variomics tool for discovering drug-resistance genes and drug targets. 12445956 - Polytherapy in epilepsy: the experimental evidence. 23021566 - Psychiatrists' decision making between branded and generic drugs. 15508776 - Malaria drug-susceptibility testing. hrp2-based assays: current data, future perspectives. 7569676 - Preclinical drug metabolism programs for food-producing animals. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2013-1-6 |
Journal Detail:
|
Title: Cancer chemotherapy and pharmacology Volume: - ISSN: 1432-0843 ISO Abbreviation: Cancer Chemother. Pharmacol. Publication Date: 2013 Jan |
Date Detail:
|
Created Date: 2013-1-7 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7806519 Medline TA: Cancer Chemother Pharmacol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Pharmaceutical Nanotechnology and Biomaterials Research Center, Faculty of Pharmacy, Shiraz University of Medical Sciences, 71345, Shiraz, Iran. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effect of HNF4? genetic polymorphism G60D on the pharmacokinetics of CYP2D6 substrate tolterodine in...
Next Document: (-)-Epigallocatechin-3-gallate inhibits human papillomavirus (HPV)-16 oncoprotein-induced angiogenes...